Platform Success Example IV

Insulin Interacting with its Full-Length Receptor

Business Need

Sanofi wanted to measure the interaction kinetics between insulin and its two binding sites on the full-length insulin receptor, with the ultimate aim to optimize the clinical efficacy of novel insulin analogues

Technical Challenge

Biophysical experiments with any full-length transmembrane receptor are a known significant challenge.


Beactica’s team of highly skilled scientists developed an experimental design for SPR biosensor-based studies of the full-length insulin receptor.


The methods developed enable accurate measurements of interaction kinetics between insulin analogues and the two binding sites of full-length insulin receptor isoform A and B.

Results from the collaboration contributed towards the regulatory approval of Insulin lispro Sanofi®, a rapid-acting insulin biosimilar introduced on the market by Sanofi.



Korn M, Wohlfart P, Gossas T, Kullman-Magnusson M, Niederhaus B, Dedio J, Tennagels N (2019) Comparison of metabolic and mitogenic response in vitro of the rapid-acting insulin lispro product SAR342434, and US- and EU-approved Humalog®. Regulatory Toxicology and Pharmacology. 109:104497.

The poster can be downloaded here Also available is a press release about the collaboration with Sanofi, see here.

Stay Updated

Sign up for the Beactica newsletter to receive our latest news and updates

This website uses cookies to improve your user experience. By continuing to browse this site, you agree to our use of cookies. More information. Ok!